BIOGEN INC. 8-K

What Happened Biogen Inc. filed an 8-K on June 10, 2026 reporting the outcomes of its 2026 Annual Meeting of Stockholders. Stockholders elected ten director nominees to one‑year terms, ratified PricewaterhouseCoopers LLP as the company’s independent auditor for fiscal 2026, and approved the advisory (non‑binding) vote on executive compensation.

• Director election vote totals (Votes For / Votes Against / Abstentions / Broker Non‑Votes = 9,359,127 for each nominee):

  • Maria C. Freire: 103,033,121 / 18,790,237 / 84,064 / 9,359,127
  • William A. Hawkins: 102,135,204 / 19,683,098 / 89,120 / 9,359,127
  • Susan K. Langer: 103,931,406 / 17,886,544 / 89,472 / 9,359,127
  • Jesus B. Mantas: 101,698,187 / 20,117,077 / 92,158 / 9,359,127
  • Lloyd Minor: 121,220,738 / 594,000 / 92,684 / 9,359,127
  • Menelas Pangalos: 121,130,060 / 682,983 / 94,379 / 9,359,127
  • Monish Patolawala: 120,796,249 / 1,016,057 / 95,116 / 9,359,127
  • Eric K. Rowinsky: 93,569,685 / 28,216,589 / 121,148 / 9,359,127
  • Stephen A. Sherwin: 103,025,923 / 18,788,272 / 93,227 / 9,359,127
  • Christopher A. Viehbacher: 121,127,966 / 688,051 / 91,405 / 9,359,127

• Auditor ratification: PricewaterhouseCoopers LLP was ratified with 124,551,887 votes for, 6,627,086 against, and 87,576 abstentions.

• Advisory executive compensation vote: Approved with 114,184,816 votes for, 7,454,737 against, 267,869 abstentions, and 9,359,127 broker non‑votes.

Why It Matters These results confirm Biogen’s board composition for the coming year and show varying levels of shareholder support across nominees — notably higher opposition for Eric K. Rowinsky (about 28.2M votes against). The ratification of PwC ensures continuity of the company’s external audit relationship for fiscal 2026. The advisory vote on executive compensation passed (non‑binding), signaling general shareholder approval but also reflecting a measurable minority dissent that investors and governance watchers may monitor.